medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-3-6-7medsovet-2997Research ArticleАКТУАЛЬНОACTUALСовременные принципы терапии воспалительных заболеваний кишечникаModern principles of treatment of inflammatory bowel diseasesРедакционнаястатьяEditorialArticle2019100520190367Copyright © Редакционная с., 20192019Редакционная с.Editorial a.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2997

Воспалительные заболевания кишечника, к которым относятся болезнь Крона и язвенный колит, по тяжести течения, частоте осложнений и летальности занимают одну из основных позиций в структуре болезней пищеварительной системы. С вопросом о современных путях решения этой значимой проблемы мы обратились к заведующему кафедрой пропедевтики внутренних болезней и гастроэнтерологии МГМСУ им. А.И. Евдокимова, академику РАН, доктору медицинских наук, профессору Игорю Вениаминовичу Маеву.

Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, in terms of severity of course, frequency of complications and lethality are among the main positions in the structure of diseases of the digestive system. With a question about modern ways of solving this important problem we addressed to Academician of the Russian Academy of Sciences, Head of the Department of Propaedeutics of Internal Diseases and Gastroenterology of A.I. Evdokimov Moscow State Medical University, Doctor of Medical Sciences, Professor Igor Veniaminovich Maev.

ReferencesИнструкция по медицинскому применению лекарственного препарата Энтивио® РУ №ЛП-003697.Инструкция по медицинскому применению лекарственного препарата Энтивио® РУ №ЛП-003697.Feagan B.G. et al. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2013;369:699-710.Feagan B.G. et al. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2013;369:699-710.Loftus E.V., et al. Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study. J Crohn’s Colitis. 2017 Feb;11(Suppl 1):S182-S183.Loftus E.V., et al. Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study. J Crohn’s Colitis. 2017 Feb;11(Suppl 1):S182-S183.Sandborn W.J., et al. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2013;369:711-21.Sandborn W.J., et al. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2013;369:711-21.Kaser A., et al. Long-term effectiveness and safety of vedolizumab in patients with Crohn’s disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI Open-Label Extension study. Gut. 2017;66(Suppl 2):A1–A288.Kaser A., et al. Long-term effectiveness and safety of vedolizumab in patients with Crohn’s disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI Open-Label Extension study. Gut. 2017;66(Suppl 2):A1–A288.Colombel J.F., et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66:839–851.Colombel J.F., et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66:839–851.

The authors declare that there are no conflicts of interest present.